News

FDA Approves First Generic Form of Oxiconazole Nitrate Cream

Author and Disclosure Information

 

References

A generic formulation of oxiconazole nitrate cream, 1% has been approved by the Food and Drug Administration, for the treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum) and tinea (pityriasis) versicolor due to Malassezia furfur.

This is the first generic version of Oxistat to be approved, according to the FDA’s statement announcing the approval.

The label for the generic, manufactured by Taro Pharmaceuticals U.S.A. is available here.

Recommended Reading

Woman Loses Weight, Gains Skin Problem
Clinician Reviews
Lesion Is Tender and Bleeds Copiously
Clinician Reviews
The Great Masquerader
Clinician Reviews
A New Approach to “Birthmarks”
Clinician Reviews
Primary Care Acne Treatment Reduces Dermatology Referrals
Clinician Reviews
VIDEO: Shingles Under 50? Look for HIV Infection
Clinician Reviews
Hemangiomas Recur in 25% of Infants After Propranolol Stopped
Clinician Reviews
Vaccine for Treating Genital Herpes Reduced Viral Shedding at 6 Months
Clinician Reviews
As Varicella Recedes, Zoster Rises: The Question Is "Why?"
Clinician Reviews
Nemolizumab Improved Most Common Symptoms in Moderate, Severe Atopic Dermatitis
Clinician Reviews